间隔期及筛查发现的乳腺癌中Her-2/neu癌基因扩增及蛋白过表达
Her-2/neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers.
作者信息
Anttinen Jorma, Kuopio Teijo, Nykanen Marjukka, Torkkeli Helena, Saari Urpo, Juhola Matti
机构信息
Department of Pathology, Jyväskylä Central Hospital, Keskussairaalantie 19, 40620 Jyväskylä, Finland.
出版信息
Anticancer Res. 2003 Sep-Oct;23(5b):4213-8.
BACKGROUND
Studies of Her-2/neu protein expression in interval and screen-detected breast cancers have been conflicting. Therefore we assessed the Her-2/neu amplification status in these groups by using in situ hybridization.
PATIENTS AND METHODS
The Her-2/neu oncogene amplification and protein over-expression were compared in 79 screen-detected and 39 interval breast carcinomas, using a novel and well-documented chromogenic in situ hybridization (CISH) method and immuhistochemistry.
RESULTS
There were 33% CISH-positive cases in the interval cancer group and only 4% CISH-positive cases in the screen-detected group. The odds ratio for interval cancer was 14.1 (95% CI 2.2 to 91.0) in the CISH-positive tumours compared with CISH-negative tumours after adjustment for nodal status, tumour size and histological grade.
CONCLUSION
Our results indicate, for the first time, that there is a clear-cut difference in Her-2/neu amplification between screen-detected and interval breast carcinomas. The amplification appears to be a rare event in screen-detected cancers but distinctly frequent in interval cancers when compared to cancers described in earlier studies.
背景
关于间期癌和筛查发现的乳腺癌中Her-2/neu蛋白表达的研究结果一直存在争议。因此，我们采用原位杂交技术评估了这些组中Her-2/neu的扩增状态。
患者与方法
采用一种新颖且记录完善的显色原位杂交（CISH）方法和免疫组化技术，对79例筛查发现的乳腺癌和39例间期乳腺癌中的Her-2/neu癌基因扩增及蛋白过表达情况进行了比较。
结果
间期癌组中CISH阳性病例占33%，而筛查发现的癌组中CISH阳性病例仅占4%。在调整淋巴结状态、肿瘤大小和组织学分级后，CISH阳性肿瘤中间期癌的优势比为14.1（95%可信区间2.2至91.0），与CISH阴性肿瘤相比。
结论
我们的结果首次表明，筛查发现的乳腺癌和间期乳腺癌在Her-2/neu扩增方面存在明显差异。与早期研究中描述的癌症相比，扩增在筛查发现的癌症中似乎是罕见事件，但在间期癌中明显更为常见。
Zotero 插件